PICOSSIDE (0.4.1)
Approved for use through 07/13/2006 (0.40) 054-030.

U.S. Peletra att (1/sekmaik Orlocy U.S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of infamination unless of contains a value of the contains and unless of contains a value.

	Application Number		
	Filing Date		2006-07-10
INFORMATION DISCLOSURE STATEMENT BY APPLICANT (Not for submission under 37 CFR 1.99)	First Named Inventor Chrys		stel CAMBUS-BRUNET
	Art Unit		
	Examiner Name		
	Attorney Docket Numb	er	21.1214

		Remove			
Cite No	Patent Number	Kind Code ¹	Issue Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
1	4606407		1986-08-19	Shu	
2	4670165		1987-06-02	Black et al.	
3	5086089		1992-02-04	Shu	
4	5642783		1997-07-01	Moradi-Araghi et al	
5	5789351		1998-08-04	Ahmed et al.	
6	5849674		1998-12-15	Fox et al.	
h to a	dd additional U.S. Pater	rt citatio	ı n information pl	lease click the Add button.	Add
		U.S.P	ATENT APPLI	CATION PUBLICATIONS	Remove
Cite No	Publication Number	Kind Code ¹	Publication Date	Name of Patentee or Applicant of cited Document	Pages,Columns,Lines where Relevant Passages or Relevant Figures Appear
	1 2 3 4 5 6 6 Cite	No Patent Number 1 4606407 2 4670165 3 5086089 4 5642783 5 5789351 6 5549674 To add additional U.S. Paten	No Patent Number Code1 1 4806407 2 4670165 3 5086089 4 5642783 5 5789351 6 5849674 1 to add additional U.S. Patent citation U.S.P. Patent U.S.P. Patent Citation U.S.P. Patent U.S.P. Pat	Cite Patent Number Kind Risue Date	No

	1										
If you wis	h to a	dd additional U.S. Publ	ished App	plication	citatio	n information p	please click the Add	buttor	n. Add	1	
				FOREIG	N PAT	ENT DOCUM	IENTS		Remove		_
Examiner Initial*	Cite No	Foreign Document Number ³	Country Code ²		Kind Code ⁴		Name of Patentee Applicant of cited Document	or	where Re	or Relevant	TS
	1	0149971	wo		A1	2001-07-12					
	2	0601988	EP			1999-09-15					
If you wis	h to a	dd additional Foreign P	atent Do	cument	citation	information pl	lease click the Add	button	Add		_
			NON	-PATEN	IT LITE	RATURE DO	CUMENTS		Remove		
Examiner Initials*	Examiner Cite include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, pages(s), volume-issue number(s), publisher, city and/or country where published.						Τs				
	1	SPE50572 - Controlling R., Renard M. Omari A.		elation of	Polyacı	ylamides by Zin	conium for Water Shu	utoff - C	haubeteau	G., Tabary	

EXAMINER SIGNATURE

Examiner Signature

Date Considered

Examiner Signature

Date Considered

Examiner Signature

Date Considered

Examiner Signature

Date Considered

If you wish to add additional non-patent literature document citation information please click the Add button Add

1 See Kina Codes of USPTO Patent Documents at yww.USPTO.COV or WIFEP 901.4. ² Earlier office that assued the document, by the how letter code (WIFPO Standard ST.3.) ² Sort Justanese patent obcoments, by mischool on the year of the Proprior must proceed the series an under the Telephore and procedures are an under to the patent document.

1 Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST.16 if possible. ³ Applicant is to place a check mark here if English language the restation is attached.

Application Number Filing Date 2006-07-10 INFORMATION DISCLOSURE First Named Inventor Chrystel CAMBUS-BRUNET STATEMENT BY APPLICANT Art I Init (Not for submission under 37 CFR 1.99) Examiner Name Attorney Docket Number 21 1214

CERTIFICATION STATEMENT

That each item of information contained in the information disclosure statement was first cited in any communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(1).

OR

That no item of information contained in the information disclosure statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to the knowledge of the person signing the certification after making reasonable inquiry, no item of information contained in the information disclosure statement was known to any individual designated in 37 CFR 1.56(c) more than three months prior to the filing of the information disclosure statement. See 37 CFR 1.97(e)(2).

- See attached certification statement
- Fee set forth in 37 CFR 1.17 (p) has been submitted herewith.

Please see 37 CFR 1.97 and 1.98 to make the appropriate selection(s):

None

SIGNATURE

A signature of the applicant or representative is required in accordance with CFR 1.33, 10.18. Please see CFR 1.4(d) for the form of the signature

Registration Number

ionii oi tiio dignataro.			
Signature	/Thomas O. Mitchell/	Date (YYYY-MM-DD)	2006-07-10
Name/Print	Thomas O. Mitchell	Registration Number	47800

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 1 hour to complete, including gathering, preparing and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, P.O. Box 1450, Alexandria, VA 22313-1450, DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Commissioner for Patents. P.O. Box 1450. Alexandria. VA 22313-1450

Privacy Act Statement

The Privacy Act of 1974 (P.L. 93-579) requires that you be given certain information in connection with your submission of the attached form related to a patient application or patient. Accordingly, pursuant to the requirements of the Act, please be advised that (1) the general authority for the collection of this information is \$3 U.S.C. 2(b)(2); (2) famishing of the information solicided is voluntary, and (3) the principal purpose for which the information is used by the U.S. Patient and Trademan Kollie is to process and/or examine your submission related to a patient application or patient. If you do not furnish the requested process and/or examine your submission related to a patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested related to the patient application or patient. If you do not furnish the requested to the patient process and/or examine your submission, which may related that the patient process and/or examine your submission, which may

The information provided by you in this form will be subject to the following routine uses:

- The information on this form will be treated confidentially to the extent allowed under the Freedom of Information Act (5 U.S.C. 552) and the Privacy Act (5 U.S.C. 552a). Records from this system of records may be disclosed to the Department of Justice to determine whether the Freedom of Information Act requires disclosure of these record s.
 - A record from this system of records may be disclosed, as a routine use, in the course of presenting evidence to a court, magistrate, or administrative tribunal, including disclosures to opposing counsel in the course of settlement neodiations.
 - A record in this system of records may be disclosed, as a routine use, to a Member of Congress submitting a request involving an individual, to whom the record partains, when the individual has requested assistance from the Member with respect to the subject matter of the record.
 - A record in this system of records may be disclosed, as a routine use, to a contractor of the Agency having need for the information in order to perform a contract. Recipients of information shall be required to comply with the requirements of the Privacy Act of 1974. as amended, pursuant to 5 U.S.C. 552a(m.).
 - A record related to an International Application filed under the Patent Cooperation Treaty in this system of records
 may be disclosed, as a routine use, to the International Bureau of the World Intellectual Property Organization, pursuant
 to the Patent Cooperation Treaty.
 - A record in this system of records may be disclosed, as a routine use, to another federal agency for purposes of National Security review (35 U.S.C. 181) and for review pursuant to the Atomic Energy Act (42 U.S.C. 218(c)).
 - 7. A record from this system of records may be disclosed, as a routine use, to the Administrator, General Services, or hisher designed, uting an inspection of records conducted by GSA as part of that agency's responsibility to recommend improvements in records management practices and programs, under authority of 44 U.S.C. 2014 and 2016. Such disclosure shall be made in accordance with the GSA regulations governing inspection of records for this purpose, and any other relevant (i.e., GSA or Commerce) directive. Such disclosure shall not be used to make relevant (ii.e., GSA).
- A record from this system of records may be disclosed, as a routine use, to the public after either publication of the application pursuant to 35 U.S. C. 12(b) or issuance of a patient pursuant to 35 U.S. C. 15.1 Further, a record may be disclosed, subject to the limitations of 37 CFR.114, as a routine use, to the public if the record via flori of mapplication which became abandoned or in which the proceedings were terminated and which application is referenced by either a published application, an application open to public inseptions or an issued patient.
 - A record from this system of records may be disclosed, as a routine use, to a Federal, State, or local law enforcement agency, if the USPTO becomes aware of a violation or potential violation of law or regulation.